De-Risking Complex Generic OSD Development

A legally designated reference product that differs in strength and indication from the originator creates an unusual starting point for a generic program. Add a poorly soluble active substance with a pronounced food effect, rapid pre-systemic metabolism and high intra-subject variability, and each development decision constrains the next.

This analysis follows a film-coated immediate release tablet through a hybrid application route, QbD-led formulation work, discriminatory dissolution method development and a full replicate crossover study using reference-scaled average bioequivalence. It also covers how early scientific advice with the regulatory authority shaped the strategy before formulation began, and how impurity risk assessments were handled along the way.

Explore the approach and the reasoning behind its key decisions.